ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) and Teleflex (NYSE:TFX – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.
Valuation and Earnings
This table compares ENDRA Life Sciences and Teleflex”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ENDRA Life Sciences | N/A | N/A | -$7.03 million | ($8.15) | -0.64 |
| Teleflex | $1.99 billion | 2.91 | -$905.64 million | ($22.80) | -5.75 |
Profitability
This table compares ENDRA Life Sciences and Teleflex’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ENDRA Life Sciences | N/A | -433.64% | -204.58% |
| Teleflex | -35.88% | 13.29% | 6.55% |
Volatility and Risk
ENDRA Life Sciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, Teleflex has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.
Insider & Institutional Ownership
1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 95.6% of Teleflex shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by insiders. Comparatively, 0.7% of Teleflex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for ENDRA Life Sciences and Teleflex, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ENDRA Life Sciences | 1 | 0 | 1 | 0 | 2.00 |
| Teleflex | 1 | 5 | 4 | 1 | 2.45 |
ENDRA Life Sciences presently has a consensus target price of $25.00, indicating a potential upside of 378.01%. Teleflex has a consensus target price of $148.00, indicating a potential upside of 12.81%. Given ENDRA Life Sciences’ higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Teleflex.
Summary
Teleflex beats ENDRA Life Sciences on 8 of the 14 factors compared between the two stocks.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
About Teleflex
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
